In a small manufacturer-sponsored study, researchers evaluated sotrastaurin (AEB071), an orally administered potent and selective pan-PKC inhibitor, to 32 patients with psoriasis, resulting in a dose-dependent improvement in psoriasis during the two-week treatment period [342]. The gene discussed is PRRT2; the disease is psoriasis.